Effectiveness of lomustine and bevacizumab in progressive glioblastoma: a meta-analysis

Jie Song1 Department of Neurosurgery, Linyi Central Hospital, Linyi, People’s Republic of China

Yue-Qin Xue2 Department of Pharmacy, Linyi Central Hospital, Linyi, People’s Republic of China

Ming-Ming Zhao3 Department of Cardiology, Linyi Central Hospital, Linyi, People’s Republic of China

Peng Xu1 Department of Neurosurgery, Linyi Central Hospital, Linyi, People’s Republic of ChinaCorrespondence[email protected]

Pages 3435-3439 | Published online: 13 Jun 2018

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

FullerGNThe WHO Classification of Tumours of the Central Nervous System, 4th editionArch Pathol Lab Med2008132690618517270
PubMed Web of Science ®Google Scholar
StuppRMasonWPvan den BentMJEuropean Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials GroupRadiotherapy plus concomitant and adjuvant temozolomide for glioblastomaN Engl J Med20053521098799615758009
PubMed Web of Science ®Google Scholar
BrennanCWVerhaakRGMcKennaATCGA Research NetworkThe somatic genomic landscape of glioblastomaCell2013155246247724120142
PubMed Web of Science ®Google Scholar
NoushmehrHWeisenbergerDJDiefesKCancer Genome Atlas Research NetworkIdentification of a CpG island methylator phenotype that defines a distinct subgroup of gliomaCancer Cell201017551052220399149
PubMed Web of Science ®Google Scholar
ParsonsDWJonesSZhangXAn integrated genomic analysis of human glioblastoma multiformeScience200832158971807181218772396
PubMed Web of Science ®Google Scholar
VerhaakRGHoadleyKAPurdomECancer Genome Atlas Research NetworkIntegrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1Cancer Cell20101719811020129251
PubMed Web of Science ®Google Scholar
Cancer Genome Atlas Research NetworkBratDJVerhaakRGAldapeKDComprehensive, integrative genomic analysis of diffuse lower-grade gliomasN Engl J Med2015372262481249826061751
PubMed Web of Science ®Google Scholar
AgnihotriSBurrellKEWolfAGlioblastoma, a brief review of history, molecular genetics, animal models and novel therapeutic strategiesArch Immunol Ther Exp (Warsz)2013611254123224339
PubMed Web of Science ®Google Scholar
Wild-BodeCWellerMRimnerADichgansJWickWSublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastomaCancer Res20016162744275011289157
PubMed Web of Science ®Google Scholar
Erdem-EraslanLvan den BentMJHoogstrateYIdentification of patients with recurrent glioblastoma who may benefit from combined bevacizumab and CCNU therapy: a report from the BELOB trialCancer Res201676352553426762204
PubMed Web of Science ®Google Scholar
TaalWOosterkampHMWalenkampAMEA randomized phase II study of bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma: the Dutch BELOB studyJ Clin Oncol201331152001
Google Scholar
PiccioniDESelfridgeJModyRRDeferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacyNeuro Oncol201416681582224627236
PubMed Web of Science ®Google Scholar
TierneyJFStewartLAGhersiDBurdettSSydesMRPractical methods for incorporating summary time-to-event data into meta-analysisTrials200781617555582
PubMed Web of Science ®Google Scholar
HigginsJPThompsonSGQuantifying heterogeneity in a meta-analysisStat Med200221111539155812111919
PubMed Web of Science ®Google Scholar
HigginsJPThompsonSGDeeksJJAltmanDGMeasuring inconsistency in meta-analysesBMJ2003327741455756012958120
PubMed Web of Science ®Google Scholar
WickWGorliaTBendszusMLomustine and bevacizumab in progressive glioblastomaN Engl J Med2017377201954196329141164
PubMed Web of Science ®Google Scholar
HeilandDHMasalhaWFrancoPMacheinMRWeyerbrockAProgression-free and overall survival in patients with recurrent glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustineJ Neurooncol2016126356757526614518
PubMed Web of Science ®Google Scholar
TaalWOosterkampHMWalenkampAMSingle-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trialLancet Oncol201415994395325035291
PubMed Web of Science ®Google Scholar
LombardiGPambukuABelluLEffectiveness of antiangiogenic drugs in glioblastoma patients: a systematic review and meta-analysis of randomized clinical trialsCrit Rev Oncol Hematol20171119410228259301
PubMed Web of Science ®Google Scholar
WickWPuduvalliVKChamberlainMCPhase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastomaJ Clin Oncol20102871168117420124186
PubMed Web of Science ®Google Scholar
BatchelorTTMulhollandPNeynsBPhase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastomaJ Clin Oncol201331263212321823940216
PubMed Web of Science ®Google Scholar
ReardonDADesjardinsAPetersKPhase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapyJ Neurooncol2011103237137920853132
PubMed Web of Science ®Google Scholar
ReardonDADesjardinsAPetersKBPhase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapyCancer2011117235351535821590689
PubMed Web of Science ®Google Scholar
BatchelorTTSorensenAGdi TomasoEAZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patientsCancer Cell2007111839517222792
PubMed Web of Science ®Google Scholar
BrandsmaDvan den BentMJPseudoprogression and pseudoresponse in the treatment of gliomasCurr Opin Neurol200922663363819770760
PubMed Web of Science ®Google Scholar
FieldKMJordanJTWenPYRosenthalMAReardonDABevacizumab and glioblastoma: scientific review, newly reported updates, and ongoing controversiesCancer20151217997100725263092
PubMed Web of Science ®Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Effectiveness of lomustine and bevacizumab in progressive glioblastoma: a meta-analysis

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Effectiveness of lomustine and bevacizumab in progressive glioblastoma: a meta-analysis

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date